These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38241776)

  • 1. The effect of p53 on the activity of NRF2 and NDRG2 genes through apoptotic pathway in IDH-wildtype glioblastoma.
    Kurdi M; Baeesa S; Fadul MM; Alkhotani A; Alkhayyat S; Karami MM; Alsinani T; Katib Y; Fathaddin AA; Faizo E; Lary AI; Almansouri M; Maghrabi Y; Alyousef MA; Addass B
    Pathol Res Pract; 2024 Feb; 254():155118. PubMed ID: 38241776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synergistic effect of IDH mutation and NDRG-2 dysregulation in the progression of WHO-grade 4 astrocytomas.
    Kurdi M; Fadul MM; Alkhayyat S; Sabbagh AJ; Alsinani T; Alkhotani A; Mulla N; Mehboob R; Fathaddin AA; Bamaga A; Faizo E; Baeesa S
    Pathol Res Pract; 2023 Aug; 248():154733. PubMed ID: 37536020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major Histocompatibility Class-I (MHC-I) downregulation in glioblastoma is a poor prognostic factor but not a predictive indicator for treatment failure.
    Butt NS; Kurdi M; Fadul MM; Hakamy S; Addas BMJ; Faizo E; Alkhayyat S; Bamaga AK; Alsinani T; Katib Y; Okal F; Maghrabi Y; Sabbagh AJ; Moshref R; Albalawi S; Alkhotani A; Mohammed F; Mulla N; Baeesa S
    Pathol Res Pract; 2023 Oct; 250():154816. PubMed ID: 37725880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creutzfeldt astrocytes may be seen in IDH-wildtype glioblastoma and retain expression of DNA repair and chromatin binding proteins.
    Ballester LY; Boghani Z; Baskin DS; Britz GW; Olsen R; Fuller GN; Powell SZ; Cykowski MD
    Brain Pathol; 2018 Nov; 28(6):1012-1019. PubMed ID: 29509313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.
    Butt N; Enani M; Alshanqiti M; Alkhotani A; Alsinani T; Karami MM; Fadul MM; Almansouri M; Hassan A; Baeesa S; Bamaga AK; Alkhayyat S; Faizo E; Kurdi M
    Folia Neuropathol; 2023; 61(3):317-325. PubMed ID: 37818692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.
    Ahmad F; Dixit D; Sharma V; Kumar A; Joshi SD; Sarkar C; Sen E
    Cell Death Dis; 2016 May; 7(5):e2213. PubMed ID: 27148686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
    Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressor candidate gene, NDRG2 is frequently inactivated in human glioblastoma multiforme.
    Zhou B; Tang Z; Deng Y; Hou S; Liu N; Lin W; Liu X; Yao L
    Mol Med Rep; 2014 Aug; 10(2):891-6. PubMed ID: 24840052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.
    Tepel M; Roerig P; Wolter M; Gutmann DH; Perry A; Reifenberger G; Riemenschneider MJ
    Int J Cancer; 2008 Nov; 123(9):2080-6. PubMed ID: 18709645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with MGMT-methylated Tumors.
    Kolodziej MA; Weischer C; Reinges MH; Uhl E; Weigand MA; Schwarm FP; Schänzer A; Acker T; Quint K; Uhle F; Stein M
    Anticancer Res; 2016 Mar; 36(3):887-97. PubMed ID: 26976975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
    Hertler C; Felsberg J; Gramatzki D; Le Rhun E; Clarke J; Soffietti R; Wick W; Chinot O; Ducray F; Roth P; McDonald K; Hau P; Hottinger AF; Reijneveld J; Schnell O; Marosi C; Glantz M; Darlix A; Lombardi G; Krex D; Glas M; Reardon DA; van den Bent M; Lefranc F; Herrlinger U; Razis E; Carpentier AF; Phillips S; Rudà R; Wick A; Tabouret E; Meyronet D; Maurage CA; Rushing E; Rapkins R; Bumes E; Hegi M; Weyerbrock A; Aregawi D; Gonzalez-Gomez C; Pellerino A; Klein M; Preusser M; Bendszus M; Golfinopoulos V; von Deimling A; Gorlia T; Wen PY; Reifenberger G; Weller M
    Eur J Cancer; 2023 Aug; 189():112913. PubMed ID: 37277265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis.
    Liu N; Wang L; Li X; Yang Q; Liu X; Zhang J; Zhang J; Wu Y; Ji S; Zhang Y; Yang A; Han H; Yao L
    Nucleic Acids Res; 2008 Sep; 36(16):5335-49. PubMed ID: 18689861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
    Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N‑Myc downstream‑regulated gene 2 suppresses the proliferation of T24 human bladder cancer cells via induction of oncosis.
    Huang J; Wu Z; Wang G; Cai Y; Cai M; Li Y
    Mol Med Rep; 2015 Oct; 12(4):5730-6. PubMed ID: 26239274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.